RVPH Stock News & Catalysts – Reviva Pharmaceuticals

FEATURED

Reviva to Participate in the Lytham Partners Fall 2026 Investor Conference

The Company invites individual and institutional investors, as well as advisors and analysts with an interest in the life sciences sector, to attend the corporate presentation at https://lythampartners.com/fall2026/

Summary

Sep 22, 2026, 8:00 AM ·Globe Newswire

RECENT

Reviva Reports Second Quarter 2026 Financial Results and Recent Business Highlights

- U.S. composition of matter patent application filed seeking accelerated review for a new form of brilaroxazine designed to extend patent life and commercial exclusivity through 2046 - - FDA feedback on use of new

Aug 12, 2026, 4:29 PM ·Globe Newswire

Life Sciences Virtual Investor Forum Presentations Now Available for On-Demand Viewing

NEW YORK, June 26, 2026 (GLOBE NEWSWIRE) -- Virtual Investor Conferences, the leading proprietary investor conference series, today announced the presentations from the June 24th & 25th Life Sciences Virtual

Jun 26, 2026, 8:35 AM ·Globe Newswire

Life Sciences Virtual Investor Forum Agenda Announced for June 24th & 25th

NEW YORK, June 23, 2026 (GLOBE NEWSWIRE) -- Virtual Investor Conferences, the leading proprietary investor conference series, today announced the agenda for the Life Sciences Virtual Investor Forum, taking place June

Jun 23, 2026, 8:35 AM ·Globe Newswire

Reviva Pharmaceuticals to Present at the Life Sciences Investor Forum on June 24th

CUPERTINO, Calif., June 23, 2026 (GLOBE NEWSWIRE) -- Reviva Pharmaceuticals Holdings, Inc. (NASDAQ:RVPH) ("Reviva" or the "Company"), a late-stage pharmaceutical company developing therapies that seek

Jun 23, 2026, 8:00 AM ·Globe Newswire

Reviva to Participate in Fireside Chat at A.G.P.'s Annual Healthcare Company Showcase

CUPERTINO, Calif., May 18, 2026 (GLOBE NEWSWIRE) -- Reviva Pharmaceuticals Holdings, Inc. (OTCQB:RVPH) ("Reviva," the "Company" "we" or "us"), a late-stage pharmaceutical company developing therapies that seek to

May 18, 2026, 8:00 AM ·Globe Newswire

Reviva Reports First Quarter 2026 Financial Results and Recent Business Highlights

- Composition of matter provisional patent application filed for a new form of brilaroxazine designed to extend patent life and commercial exclusivity through 2046 - - FDA feedback on use of new form of brilaroxazine in

May 13, 2026, 4:35 PM ·Globe Newswire

Reviva to Participate in a Fireside Chat Hosted by A.G.P. on Brilaroxazine's Potential Across Multiple Neuropsychiatric Indications

CUPERTINO, Calif., April 23, 2026 (GLOBE NEWSWIRE) -- Reviva Pharmaceuticals Holdings, Inc. (NASDAQ:RVPH) ("Reviva," the "Company" "we" or "us"), a late-stage pharmaceutical company developing therapies that seek to

Apr 23, 2026, 8:00 AM ·Globe Newswire

Reviva Announces Letter to Shareholders

CUPERTINO, Calif., April 15, 2026 (GLOBE NEWSWIRE) -- Reviva Pharmaceuticals Holdings, Inc. (NASDAQ:RVPH) ("Reviva," the "Company" "we" or "us"), a late-stage pharmaceutical company developing therapies that seek to

Apr 15, 2026, 8:00 AM ·Globe Newswire

Reviva Reports Full Year 2025 Financial Results and Recent Business Highlights

- Written FDA recommendations include a second Phase 3 trial to generate additional efficacy and safety data prior to NDA submission of brilaroxazine for schizophrenia – - Current data package highlights well-tolerated

Mar 30, 2026, 6:05 AM ·Globe Newswire

Reviva Pharmaceuticals Holdings, Inc. Announces Closing of $10 Million Public Offering

CUPERTINO, Calif., March 23, 2026 (GLOBE NEWSWIRE) -- Reviva Pharmaceuticals Holdings, Inc. (NASDAQ:RVPH) ("Reviva" or the "Company"), a late-stage pharmaceutical company developing therapies that seek to address unmet

Mar 23, 2026, 8:00 AM ·Globe Newswire

Reviva Pharmaceuticals Holdings, Inc. Announces Pricing of $10 Million Public Offering

CUPERTINO, Calif., March 18, 2026 (GLOBE NEWSWIRE) -- Reviva Pharmaceuticals Holdings, Inc. (NASDAQ:RVPH) ("Reviva" or the "Company"), a late-stage pharmaceutical company developing therapies that seek to address unmet

Mar 18, 2026, 10:34 PM ·Globe Newswire

Reviva Pharmaceuticals Holdings, Inc. Announces Proposed Public Offering

Mar 18, 2026, 4:10 PM ·Globe Newswire

Reviva Announces Publication on Clinical Vocal Biomarker Data from the RECOVER Phase 3 Clinical Trial of Brilaroxazine to Treat Negative Symptoms in Schizophrenia

Findings reinforce brilaroxazine's treatment effect on negative symptoms and other symptom domains in schizophrenia and support clinician-assessed efficacy outcomes in a Phase 3 trial of brilaroxazine Findings also

Jan 8, 2026, 8:00 AM ·Globe Newswire

Reviva to Present at the Sachs 9th Annual Neuroscience Innovation Forum

CUPERTINO, Calif., Dec. 29, 2025 (GLOBE NEWSWIRE) -- Reviva Pharmaceuticals Holdings, Inc. (NASDAQ:RVPH) ("Reviva" or the "Company"), a late-stage pharmaceutical company developing therapies that seek to address unmet

Dec 29, 2025, 8:00 AM ·Globe Newswire

Reviva Pharmaceuticals Holdings, Inc. RVPH · News